Table 3.

Predicted numbers of subjects achieving factor VIII trough levels of >1% or > 3% following single or multiple doses of BAY 94-9027 or single doses of sucrose-formulated recombinant FVIII (rFVIII-FS)

Days after dosing	BAY 94-9027			rFVIII-FS
25 IU kg−1, single dose (n = 7)	25 IU kg−1, multiple doses (n = 7)	60 IU kg−1, single dose (n = 7)	60 IU kg−1, multiple doses (n = 7)	25 IU kg−1, single dose (n = 7)	50 IU kg−1, single dose (n = 7)
Subjects with FVIII trough levels of > 1%, n
2	7	7	7	7	6	7
3	7	7	7	7	4	6
4	5	6	7	7	1	3
5	1	2	6	6	1	1
6	1	2	2	3	0	0
≥ 7	1	1	1	2	0	0
Subjects with FVIII trough levels of > 3%, n
2	7	7	7	7	4	7
3	4	6	7	7	1	4
4	1	2	6	6	0	1
5	1	1	1	2	0	0
6	0	0	1	2	0	0
≥ 7	0	0	0	0	0	0